Clinical Trials Logo

Cutaneous Leishmaniasis clinical trials

View clinical trials related to Cutaneous Leishmaniasis.

Filter by:

NCT ID: NCT00121862 Completed - Clinical trials for Cutaneous Leishmaniasis

Study to Evaluate the Leish-111f + MPL-SE Vaccine in Healthy Adults Not Previously Exposed to Leishmania Parasite

Start date: August 2005
Phase: Phase 2
Study type: Interventional

This study will evaluate the safety and immunogenicity of the Leish-111f + MPL-SE vaccine in adult subjects who have no evidence of previous exposure to the Leishmania parasite.

NCT ID: NCT00121849 Completed - Clinical trials for Cutaneous Leishmaniasis

Safety Study to Evaluate the Leish-111f + MPL-SE Vaccine in the Prevention of Cutaneous Leishmaniasis in Healthy Subjects Previously Exposed to the Leishmania Parasite

Start date: August 2005
Phase: Phase 1
Study type: Interventional

This study will evaluate the safety of the Leish-111f + MPL-SE vaccine in adult subjects with a previous exposure to the Leishmania parasite (but without current or past history of leishmaniasis).

NCT ID: NCT00001906 Completed - Clinical trials for Cutaneous Leishmaniasis

Safety and Immunogenicity of a Vaccine for Cutaneous Leishmaniasis Using Recombinant Human Interleukin-12 and Aluminum Hydroxide Gel as Adjuvants

Start date: April 1999
Phase: Phase 1
Study type: Interventional

While vaccination against cutaneous leishmaniasis, a chronic ulcerating protozoan infection of the skin, has been possible for decades using live parasites, the production and storage of live cultures are difficult. Since inoculation occasionally leads to severe infection, most experts now advocate against their use. We have shown excellent protection using a "heat-killed" vaccine that combines autoclaved leishmania antigen with recombinant human interleukin-12 (rhIL-12) and aluminum hydroxide gel as adjuvants in a rhesus macaque model of disease. To assess the safety and immunogenicity of this vaccine in humans, we now propose a rhIL-12 dose escalation Phase I/II trial.